Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Tuesday, 22'nd Jul 2025
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
10:41am, Tuesday, 22'nd Jul 2025
Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
01:29pm, Monday, 21'st Jul 2025
Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.
– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixore
Alkermes to Report Second Quarter Financial Results on July 29, 2025
04:00pm, Tuesday, 15'th Jul 2025
DUBLIN , July 15, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%
10:55am, Monday, 14'th Jul 2025
The consensus price target hints at a 33.2% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
10:30am, Wednesday, 02'nd Jul 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 01'st Jul 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks pre
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
04:00pm, Monday, 02'nd Jun 2025
DUBLIN , June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Co
Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences
07:00am, Monday, 02'nd Jun 2025
– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN , June 2, 2025 /PRNewswire/ --
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
12:10pm, Friday, 02'nd May 2025
ALKS' earnings and revenues lag first-quarter 2025 estimates. Sales of proprietary products surpass management's expectations.
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
04:31pm, Thursday, 01'st May 2025
The company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings
12:00pm, Thursday, 01'st May 2025
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare
Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript
11:21am, Thursday, 01'st May 2025
Alkermes plc (NASDAQ:ALKS ) Q1 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Sandy Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard Pops -
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates
09:26am, Thursday, 01'st May 2025
Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago.
